LYCOS RETRIEVER 
Surface: Surface Logix
built 657 days ago
BOSTON, Jan. 8 /PRNewswire/ -- Surface Logix today announced positive results in the Company's Phase 2a clinical trial of SLx-2101 in hypertension. The randomized, double-blind, placebo-controlled crossover Phase 2a study in 60 patients with uncontrolled hypertension demonstrated that SLx-2101 caused clinically significant reductions in blood pressure and was well tolerated. The trial was designed to examine the safety, tolerability and effect on blood pressure in patients of repeat oral doses of SLx-2101 once daily for up to 14 days.
Source:
BOSTON, Nov. 30 /PRNewswire/ -- Surface Logix today announced the commencement of a company-sponsored Phase IIa clinical trial for SLx-2101, a new potent and selective long-acting, oral PDE5 inhibitor. SLx-2101 is being evaluated for the treatment of vascular and cardiovascular disease where endothelial dysfunction is a significant component of the pathogenesis of the disease.
Source:
Surface Logix uses its expertise in biophysical chemistry to create and develop novel small molecule drugs (NCEs) with superior intrinsic drug-like properties that are clearly differentiated from competitive products. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. For more information, please visit http://www.surfacelogix.com.
Source:
"It is exciting that this novel compound continued to perform so well in this first repeat-dose study," said Dr. William Prince, Chief Development Officer of Surface Logix. "Consistent with our preclinical and Phase 1 single-dose results, no drug was detected in the plasma at doses up to 200 mg given three times daily for two weeks. This is particularly notable, as all other known MTP inhibitors have been shown to enter the systemic circulation and negatively impact standard measures of liver function. SLx-4090 was extremely well tolerated and adverse events were similar to those seen with placebo."
Source:
SLx-2101 is an oral phosphodiesterase-5 (PDE-5) inhibitor designed using Surface Logix' proprietary small molecule Pharmacomer(TM) Technology. SLx- 2101 is being developed to treat endothelial dysfunction, a physiological disability of endothelial cells, the cells that line the inner surface of all blood vessels, arteries and veins, that prevents them from carrying out their normal biochemical functions. Normal endothelial cells are involved in mediating the processes of coagulation, platelet adhesion, immune function, control of volume and electrolyte content of the intravascular and extravascular spaces. Endothelial dysfunction is believed to be the underlying cause for several major diseases including atherosclerosis, congestive heart failure, hypertension and erectile dysfunction.
Source:
MORE ABOUT
Surface Logix